Unknown

Dataset Information

0

Intramuscular Adeno-Associated Virus-Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice.


ABSTRACT: The 2013-2016 West Africa outbreak demonstrated the epidemic potential of Ebola virus and highlighted the need for counter strategies. Monoclonal antibody (mAb)-based therapies hold promise as treatment options for Ebola virus infections. However, production of clinical-grade mAbs is labor intensive, and immunity is short lived. Conversely, adeno-associated virus (AAV)-mediated mAb gene transfer provides the host with a genetic blueprint to manufacture mAbs in vivo, leading to steady release of antibody over many months. Here we demonstrate that AAV-mediated expression of nonneutralizing mAb 5D2 or 7C9 confers 100% protection against mouse-adapted Ebola virus infection, while neutralizing mAb 2G4 was 83% protective. A 2-component cocktail, AAV-2G4/AAV-5D2, provided complete protection when administered 7 days prior to challenge and was partially protective with a 3-day lead time. Finally, AAV-mAb therapies provided sustained protection from challenge 5 months following AAV administration. AAV-mAb may be a viable alternative strategy for vaccination against emerging infectious diseases.

SUBMITTER: van Lieshout LP 

PROVIDER: S-EPMC5853240 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Intramuscular Adeno-Associated Virus-Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice.

van Lieshout Laura P LP   Soule Geoff G   Sorensen Debra D   Frost Kathy L KL   He Shihua S   Tierney Kevin K   Safronetz David D   Booth Stephanie A SA   Kobinger Gary P GP   Qiu Xiangguo X   Wootton Sarah K SK  

The Journal of infectious diseases 20180301 6


The 2013-2016 West Africa outbreak demonstrated the epidemic potential of Ebola virus and highlighted the need for counter strategies. Monoclonal antibody (mAb)-based therapies hold promise as treatment options for Ebola virus infections. However, production of clinical-grade mAbs is labor intensive, and immunity is short lived. Conversely, adeno-associated virus (AAV)-mediated mAb gene transfer provides the host with a genetic blueprint to manufacture mAbs in vivo, leading to steady release of  ...[more]

Similar Datasets

| S-EPMC3497800 | biostudies-other
| S-EPMC11348817 | biostudies-literature
| S-EPMC4867612 | biostudies-literature
| S-EPMC6102396 | biostudies-literature
| S-EPMC11009494 | biostudies-literature
| S-EPMC7153831 | biostudies-literature
| S-EPMC4702560 | biostudies-literature
| S-EPMC8435780 | biostudies-literature
| S-EPMC7358261 | biostudies-literature
| S-EPMC6298217 | biostudies-literature